Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06286098
Other study ID # ALA in Pediatrics on HD
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date March 20, 2024
Est. completion date October 20, 2024

Study information

Verified date February 2024
Source Ain Shams University
Contact Mahmoud Mohsen, Pharmacist
Phone +201275811494
Email mahmoudfast41@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test alpha lipoic acid in children undergoing hemodialysis. The main questions it aims to answer are: - Will the use of alpha lipoic acid lower cardiovascular events in that population? - Is the incidence of those cardiovascular events linked to the oxidative stress and endothelial dysfunction in that population? - Will the drug cause side effects? Participants will: - take either one dose daily of 600mg tablet Alpha lipoic acid orally or a look-alike tablet containing no drug. - be monitored for the occurrence of cardiovascular events (stroke, angina, etc.) - be monitored for the occurrence of side effects - give blood samples for testing serum levels of E-selectin biomarker and superoxide dismutase enzyme - undergo clinical examinations (Echocardiogram, Duplex ultrasonography, Intima-Media-Thickness) Researchers will compare between the group taking alpha lipoic acid and the group taking the look-alike tablet.


Description:

A Double-Blinded, Paralleled, Randomized, Placebo-Controlled Clinical Trial will be conducted at the Pediatric Nephrology and Dialysis Unit, Children's Hospital, Ain Shams University, Cairo, Egypt to detect the efficacy of alpha lipoic acid in reducing cardiovascular events by reducing oxidative stress-mediated endothelial dysfunction in pediatric population on regular hemodialysis by assessment of: 1. E-selectin as an Endothelial biomarker 2. SOD as an Oxidative stress biomarker 3. Indicators of CVS dysfunction by; - Duplex ultrasonography - Echocardiogram with stress on Ejection Fraction - Intimal medial thickness 4. Occurrence of CVS events


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date October 20, 2024
Est. primary completion date September 20, 2024
Accepts healthy volunteers No
Gender All
Age group 8 Years to 16 Years
Eligibility Inclusion Criteria: - Pediatric participants admitted to Pediatric Hemodialysis Unit for regular hemodialysis. - The ability to swallow capsules will be enrolled in the study. Exclusion Criteria: - Participants who suffered from any previous cardiovascular event. - Participants suffering from inflammatory diseases or other diseases that may increase oxidative stress. - Participants taking supplements that decrease oxidative stress or inflammatory markers - Participants with hypersensitivity to alpha lipoic acid - Participants who are non-compliant.

Study Design


Intervention

Drug:
Alpha lipoic acid
THIOTACID 600 MG ORIGINAL ® Tablets manufactured by EVA PHARMA
Other:
Placebo
Placebo identical Tablets are manufactured by EVA PHARMA containing the same excipients without Alpha Lipoic Acid.

Locations

Country Name City State
Egypt New Pediatrics Hospital, Faculty of Medicine, Ain Shams University Cairo El Weili

Sponsors (2)

Lead Sponsor Collaborator
Ain Shams University Eva Pharma

Country where clinical trial is conducted

Egypt, 

References & Publications (6)

Al-Nami MS, Al-Kuraishy HM, Al-Gareeb AI. Impact of thioctic acid on glycemic indices and associated inflammatory-induced endothelial dysfunction in patients with type 2 diabetes mellitus: A case control study. Int J Crit Illn Inj Sci. 2020 Sep;10(Suppl 1):21-27. doi: 10.4103/IJCIIS.IJCIIS_62_19. Epub 2020 Sep 16. — View Citation

Fogacci F, Rizzo M, Krogager C, Kennedy C, Georges CMG, Knezevic T, Liberopoulos E, Vallee A, Perez-Martinez P, Wenstedt EFE, Satrauskiene A, Vrablik M, Cicero AFG. Safety Evaluation of alpha-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. Antioxidants (Basel). 2020 Oct 19;9(10):1011. doi: 10.3390/antiox9101011. — View Citation

Haghighatdoost F, Hariri M. The effect of alpha-lipoic acid on inflammatory mediators: a systematic review and meta-analysis on randomized clinical trials. Eur J Pharmacol. 2019 Apr 15;849:115-123. doi: 10.1016/j.ejphar.2019.01.065. Epub 2019 Feb 2. — View Citation

Huang EA, Gitelman SE. The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2008 Jun;9(3 Pt 2):69-73. doi: 10.1111/j.1399-5448.2007.00342.x. Epub 2008 Jan 22. — View Citation

Li LC, Tain YL, Kuo HC, Hsu CN. Cardiovascular diseases morbidity and mortality among children, adolescents and young adults with dialysis therapy. Front Public Health. 2023 Apr 12;11:1142414. doi: 10.3389/fpubh.2023.1142414. eCollection 2023. — View Citation

Malatino LS, Stancanelli B, Cataliotti A, Bellanuova I, Fatuzzo P, Rapisarda F, Leonardis D, Tripepi G, Mallamaci F, Zoccali C. Circulating E-selectin as a risk marker in patients with end-stage renal disease. J Intern Med. 2007 Oct;262(4):479-87. doi: 10.1111/j.1365-2796.2007.01841.x. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Serum level of E-Selectin The effect of ALA supplementation on the serum level of E-Selectin in pediatric patients on regular hemodialysis. at baseline and after the duration of treatment (6 months)
Secondary Serum levels of superoxide dismutase (SOD) The effect of ALA supplementation on the serum level of SOD in pediatric patients on regular hemodialysis. at baseline and after the duration of treatment (6 months)
Secondary Number of cardiovascular events Counting the number of cardiovascular events (stroke, angina, etc.) through monitoring for the duration of treatment (6 months)
Secondary Number of Adverse effects Evaluation of the safety of ALA supplementation in pediatric hemodialysis patients in terms of proportion of adverse drug events and complications. for the duration of treatment (6 months)
See also
  Status Clinical Trial Phase
Completed NCT05980845 - The Effect Nature Sounds and Music on Hemodialysis Patients N/A
Recruiting NCT05020717 - Retrospective Survey of Hyperkalemia in Hemodialysis
Recruiting NCT04046042 - Virtual Reality Intradialysis: Last vs. First Part of the Session N/A
Recruiting NCT04094038 - The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients Phase 4
Completed NCT03311581 - The Feasibility of Propofol TCI in Hemodialysis Patients Undergoing Arteriovenous Shunt Surgery Phase 1
Completed NCT05531175 - REIKI APPLICATION PAIN, FATIGUE AND ITCHING IN HEMODIALYSIS PATIENTS N/A
Completed NCT04057313 - Coffee in Hemodialysis and Headache N/A
Completed NCT03061552 - Inferior Vena Cava Sonography in Hemodialysis Patients and Quality of Life N/A
Completed NCT03251573 - The Cohort Study of Cognitive Impairment in Chinese Hemodialysis Patients
Completed NCT03527680 - Effect of Lactobacillus Rhamnosus on Serum Uremic Toxins in Hemodialysis N/A
Completed NCT05568342 - The Effect of Roy Adaptation-Based Nursing Intervention N/A
Completed NCT04063423 - Non- Clinical Coagulation Activation During Hemodialysis
Active, not recruiting NCT06203795 - Dialysis Performance of the FX CorAL Membrane N/A
Completed NCT04319328 - Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
Completed NCT03627884 - Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation Phase 4
Completed NCT05132036 - Lung Ultrasound Assessment of Fluid Overload in Haemodialysis Patients N/A
Completed NCT03076528 - An Innovative Virtually Supervised Exercise for Dialysis Patients Phase 2
Completed NCT06098443 - Acupressure Versus Transcutaneous Electrical Nerve Stimulation on Pain and Quality of Life Intradialysis N/A
Completed NCT04645121 - Carbon Monoxide-based Rebreathing Method and Bioimpedance in Hemodialysis Patients
Recruiting NCT04127877 - Bio Impedance-assisted Monitoring of Chronic Hemodialysis Patients N/A